Drug Discovery

Kite, Gadeta collaborate to advance gamma delta T cell receptor technology for solid tumors

Kite and Gadeta have entered into a strategic collaboration to develop novel gamma delta TCR therapies in various cancers.

Cambrex to buy Halo Pharma for $425m

Cambrex has agreed to acquire contract development and manufacturing organization (CDMO) Halo Pharma for about $425m.

Novartis to pay EUR95m to Galapagos and MorphoSys for skin drug rights

Novartis has agreed to make an upfront payment of EUR95m to Galapagos and MorphoSys to in-license IL-17C compound for atopic dermatitis.

Genmab, Immatics to develop next-generation bispecific cancer immunotherapies

Genmab has signed a collaboration and exclusive license agreement with Immatics Biotechnologies to work on next-generation bispecific cancer immunotherapies.

Otsuka Pharmaceutical to buy biotechnology firm Visterra for $430m

Otsuka Pharmaceutical has agreed to acquire clinical-stage biotechnology firm Visterra for around $430m.

BioCryst terminates merger deal with Idera Pharmaceuticals

BioCryst Pharmaceuticals has failed to get approval from the stockholders for its merger deal with Idera Pharmaceuticals.

Amryt secures funding approval from NHS England for bad cholesterol treatment

Biopharmaceutical firm Amryt has secured approval for funding from NHS England for its bad cholesterol treatment, Lojuxta (lomitapide).

Axovant, Benitec sign licensing deal for AXO-AAV-OPMD program

Axovant Sciences has entered into a global licensing agreement with Benitec Biopharma for BB-301 (AXO-AAV-OPMD) platform to treat oculopharyngeal muscular dystrophy (OPMD).

Catalent to buy Juniper Pharmaceuticals in $133m deal

US-based Catalent has agreed to acquire Juniper Pharmaceuticals in a deal valued at around $133m.